OA19692A - Combination therapies of hepatitis B virus (HBV)-infected individuals using Parapoxvirus ovis (PPVO) and at least one further antiviral drug. - Google Patents
Combination therapies of hepatitis B virus (HBV)-infected individuals using Parapoxvirus ovis (PPVO) and at least one further antiviral drug. Download PDFInfo
- Publication number
- OA19692A OA19692A OA1202000103 OA19692A OA 19692 A OA19692 A OA 19692A OA 1202000103 OA1202000103 OA 1202000103 OA 19692 A OA19692 A OA 19692A
- Authority
- OA
- OAPI
- Prior art keywords
- ppvo
- antiviral drug
- hbv
- effective amount
- different antiviral
- Prior art date
Links
- 239000003443 antiviral agent Substances 0.000 title claims abstract description 129
- 241000283898 Ovis Species 0.000 title claims abstract description 21
- 241000700639 Parapoxvirus Species 0.000 title claims abstract description 21
- 241000700721 Hepatitis B virus Species 0.000 title claims description 81
- 238000002648 combination therapy Methods 0.000 title abstract description 3
- QDGZDCVAUDNJFG-FXQIFTODSA-N Entecavir Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)C1=C QDGZDCVAUDNJFG-FXQIFTODSA-N 0.000 claims abstract description 80
- 229960000980 entecavir Drugs 0.000 claims abstract description 80
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 40
- 239000003112 inhibitor Substances 0.000 claims abstract description 36
- 230000001939 inductive effect Effects 0.000 claims abstract description 16
- -1 e.g. Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 102
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 48
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 39
- 210000004185 Liver Anatomy 0.000 claims description 36
- 108020004707 nucleic acids Proteins 0.000 claims description 30
- 230000000051 modifying Effects 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 102000004965 antibodies Human genes 0.000 claims description 20
- 108090001123 antibodies Proteins 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 19
- 230000003612 virological Effects 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 18
- 210000002845 Virion Anatomy 0.000 claims description 16
- 230000000840 anti-viral Effects 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 229940079593 drugs Drugs 0.000 claims description 15
- 230000001684 chronic Effects 0.000 claims description 14
- 101700052274 HBEAG Proteins 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 12
- 238000001802 infusion Methods 0.000 claims description 12
- 239000002674 ointment Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 10
- 238000001990 intravenous administration Methods 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 8
- 210000000234 Capsid Anatomy 0.000 claims description 8
- 229960004693 Tenofovir disoproxil fumarate Drugs 0.000 claims description 8
- 230000014509 gene expression Effects 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 8
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 8
- 102000002689 toll-like receptors Human genes 0.000 claims description 8
- 108020000411 toll-like receptors Proteins 0.000 claims description 8
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims description 7
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 201000004044 liver cirrhosis Diseases 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 230000001629 suppression Effects 0.000 claims description 7
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 206010019641 Hepatic cirrhosis Diseases 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- 229940047124 Interferons Drugs 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 239000002955 immunomodulating agent Substances 0.000 claims description 6
- 230000002584 immunomodulator Effects 0.000 claims description 6
- 229940121354 immunomodulators Drugs 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 6
- 239000007937 lozenge Substances 0.000 claims description 6
- 231100000486 side effect Toxicity 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 210000001519 tissues Anatomy 0.000 claims description 6
- 241000700739 Hepadnaviridae Species 0.000 claims description 5
- 229960004556 Tenofovir Drugs 0.000 claims description 5
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N Tenofovir Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 claims description 5
- 230000001900 immune effect Effects 0.000 claims description 5
- XQSPYNMVSIKCOC-NTSWFWBYSA-N (2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-Pyrimidinone Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 4
- SUPKOOSCJHTBAH-UHFFFAOYSA-N 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 claims description 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 4
- 241000701242 Adenoviridae Species 0.000 claims description 4
- 241000712892 Arenaviridae Species 0.000 claims description 4
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N Clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 4
- 241001533413 Deltavirus Species 0.000 claims description 4
- 241000710781 Flaviviridae Species 0.000 claims description 4
- 241000700586 Herpesviridae Species 0.000 claims description 4
- 229960001627 Lamivudine Drugs 0.000 claims description 4
- 241000712464 Orthomyxoviridae Species 0.000 claims description 4
- 241000711504 Paramyxoviridae Species 0.000 claims description 4
- 241000701945 Parvoviridae Species 0.000 claims description 4
- 241000150350 Peribunyaviridae Species 0.000 claims description 4
- 241001631648 Polyomaviridae Species 0.000 claims description 4
- 241000700625 Poxviridae Species 0.000 claims description 4
- 230000025458 RNA interference Effects 0.000 claims description 4
- 241000702247 Reoviridae Species 0.000 claims description 4
- 241000712907 Retroviridae Species 0.000 claims description 4
- 241000711931 Rhabdoviridae Species 0.000 claims description 4
- IQFYYKKMVGJFEH-CSMHCCOUSA-N Telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims description 4
- 241000710924 Togaviridae Species 0.000 claims description 4
- 230000001154 acute Effects 0.000 claims description 4
- 229960001997 adefovir Drugs 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 229960005338 clevudine Drugs 0.000 claims description 4
- 239000000134 cyclophilin inhibitor Substances 0.000 claims description 4
- 229960000366 emtricitabine Drugs 0.000 claims description 4
- 230000001973 epigenetic Effects 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 230000001717 pathogenic Effects 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 229960005311 telbivudine Drugs 0.000 claims description 4
- 230000001225 therapeutic Effects 0.000 claims description 4
- 238000002255 vaccination Methods 0.000 claims description 4
- 239000003607 modifier Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 230000000699 topical Effects 0.000 claims description 3
- 206010067125 Liver injury Diseases 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000005755 formation reaction Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000002489 hematologic Effects 0.000 claims description 2
- 231100000234 hepatic damage Toxicity 0.000 claims description 2
- 230000002829 reduced Effects 0.000 claims description 2
- 230000001743 silencing Effects 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 abstract description 5
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract description 5
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 47
- 241000283923 Marmota monax Species 0.000 description 39
- 210000004027 cells Anatomy 0.000 description 20
- 210000004369 Blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 230000004044 response Effects 0.000 description 18
- 238000001574 biopsy Methods 0.000 description 13
- 102000006640 EC 2.3.2.2 Human genes 0.000 description 9
- 108020004206 EC 2.3.2.2 Proteins 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 239000000969 carrier Substances 0.000 description 8
- 238000009097 single-agent therapy Methods 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 230000002354 daily Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000038129 antigens Human genes 0.000 description 6
- 108091007172 antigens Proteins 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000002459 sustained Effects 0.000 description 6
- 102000006992 Interferon-alpha Human genes 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 230000021633 leukocyte mediated immunity Effects 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000003442 weekly Effects 0.000 description 5
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 4
- 102100013658 SORD Human genes 0.000 description 4
- 210000001744 T-Lymphocytes Anatomy 0.000 description 4
- 201000009673 liver disease Diseases 0.000 description 4
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 101700086956 IFNG Proteins 0.000 description 3
- 102100016020 IFNG Human genes 0.000 description 3
- 229940100601 Interleukin-6 Drugs 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 206010058874 Viraemia Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 210000000056 organs Anatomy 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002195 synergetic Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 101710027066 ALB Proteins 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 108010082126 Alanine Transaminase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 210000001185 Bone Marrow Anatomy 0.000 description 2
- 210000000988 Bone and Bones Anatomy 0.000 description 2
- 101700045471 CD79B Proteins 0.000 description 2
- 102100019449 CD79B Human genes 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 210000003743 Erythrocytes Anatomy 0.000 description 2
- 102100015239 F2 Human genes 0.000 description 2
- 102100012318 F3 Human genes 0.000 description 2
- IRHZVMHXVHSMKB-UHFFFAOYSA-N Fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 description 2
- 102100010966 GPT Human genes 0.000 description 2
- 102000016901 Glutamate dehydrogenases Human genes 0.000 description 2
- 108091000037 Glutamate dehydrogenases Proteins 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 210000000265 Leukocytes Anatomy 0.000 description 2
- 210000001165 Lymph Nodes Anatomy 0.000 description 2
- 102100007544 NCAM1 Human genes 0.000 description 2
- 101700077124 NCAM1 Proteins 0.000 description 2
- 210000000440 Neutrophils Anatomy 0.000 description 2
- 229940039716 Prothrombin Drugs 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 210000003324 RBC Anatomy 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 101710040537 TNF Proteins 0.000 description 2
- 102100009534 TNF Human genes 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 230000036462 Unbound Effects 0.000 description 2
- 210000000626 Ureter Anatomy 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N Xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 Xylazine Drugs 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002153 concerted Effects 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002440 hepatic Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000004450 types of analysis Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccines Drugs 0.000 description 2
- 108020004463 18S Ribosomal RNA Proteins 0.000 description 1
- 229920002483 18S ribosomal RNA Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 210000004100 Adrenal Glands Anatomy 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 210000000709 Aorta Anatomy 0.000 description 1
- 210000003651 Basophils Anatomy 0.000 description 1
- BVGLIYRKPOITBQ-ANPZCEIESA-N Benzathine benzylpenicillin Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 BVGLIYRKPOITBQ-ANPZCEIESA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- NNUSCVFWUPARGJ-UHFFFAOYSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=NC(CC=2[C](C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N=2)CCC(O)=O)=C(CCC(O)=O)[C]1C NNUSCVFWUPARGJ-UHFFFAOYSA-N 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 210000000621 Bronchi Anatomy 0.000 description 1
- 102100003268 CD14 Human genes 0.000 description 1
- 101700027514 CD14 Proteins 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 210000004534 Cecum Anatomy 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- 229920002759 Circular DNA Polymers 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004420 EC 2.7.3.2 Human genes 0.000 description 1
- 108010042126 EC 2.7.3.2 Proteins 0.000 description 1
- 210000003979 Eosinophils Anatomy 0.000 description 1
- 210000001508 Eye Anatomy 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 210000000232 Gallbladder Anatomy 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- WZUVPPKBWHMQCE-VYIIXAMBSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@@]2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-VYIIXAMBSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 208000002672 Hepatitis B Diseases 0.000 description 1
- 206010062060 Hyperlipidaemia Diseases 0.000 description 1
- 241001662043 Icterus Species 0.000 description 1
- 210000003405 Ileum Anatomy 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 210000000867 Larynx Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 210000002264 Mammary Glands, Animal Anatomy 0.000 description 1
- 210000004293 Mammary Glands, Human Anatomy 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 241001244708 Moroccan pepper virus Species 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 210000001328 Optic Nerve Anatomy 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 210000003101 Oviducts Anatomy 0.000 description 1
- 229940078666 Panacur Drugs 0.000 description 1
- 210000002990 Parathyroid Glands Anatomy 0.000 description 1
- 210000001986 Peyer's Patches Anatomy 0.000 description 1
- 210000003635 Pituitary Gland Anatomy 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 210000003079 Salivary Glands Anatomy 0.000 description 1
- 210000003497 Sciatic Nerve Anatomy 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 210000000278 Spinal Cord Anatomy 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 210000001562 Sternum Anatomy 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 210000001541 Thymus Gland Anatomy 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 210000002105 Tongue Anatomy 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 210000003437 Trachea Anatomy 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 210000001215 Vagina Anatomy 0.000 description 1
- URRBLVUOXIGNQR-HXUWFJFHSA-N [(1R)-1-phenylethyl] N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]carbamate Chemical compound C1([C@@H](C)OC(=O)N(CCN)CC=2C=C(C(=CC=2)OCC=2C=CC=CC=2)OC)=CC=CC=C1 URRBLVUOXIGNQR-HXUWFJFHSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- BPYKTIZUTYGOLE-IFADSCNNSA-N bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960005473 fenbendazole Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002949 hemolytic Effects 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 230000004380 optic nerve Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000000405 serological Effects 0.000 description 1
- 230000001340 slower Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 231100000730 tolerability Toxicity 0.000 description 1
- 230000002110 toxicologic Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Abstract
The present invention relates to new combination therapies of HBV-infected individuals using a Parapoxvirus ovis (PPVO) and at least one further antiviral drug, e.g., nucleoside inhibitors, such as Entecavir. The methods and combination products according to the present invention are safe and suitable for the induction of a functional cure in chronically HBV-infected patients.
Description
Combination thérapies of Hepatitis B Virus (HBV)-infected individuals using Parapoxvirus ovis (PPVO) and at least one further antiviral drug
Technical field
The présent invention relates to new combination thérapies of HBV-infected individuals using a Parapoxvirus ovis (PPVO) and at least one further antiviral drug, e.g., nucleoside inhibitors, such as Entecavir. The methods and combination products according to the présent invention are safe 10 and suitable for the induction of a functional cure in chronically HBV-infected patients.
Background
Hepatitis B Virus (HBV) is an enveloped, partially double-stranded DNA (dsDNA) virus of the 15 hepadnavirus family (Hepadnaviridae). Chronic HBV infection is a significant global health problem, affecting over 5% of the world population (over 350 million people worldwide and 1.25 million individuals in the US).
Despite the availability of a prophylactic HBV vaccine, the burden of chronic HBV infection 20 continues to be a significant unmet worldwide medical problem, due to suboptimal treatment options and sustained rates of new infections in most parts of the developing world. Current treatments do not provide a cure and are limited to only two classes of agents (interferon alpha and nucleoside/nucleotide analogues/inhibitors of the viral polymerase); drug résistance, low efficacy, and tolerability issues limit their impact.
The low cure rates of HBV are attributed at least in part to the fact that complété suppression of virus production is difficult to achieve with a single antiviral agent, and to the presence and persistence of covalently closed circular DNA (cccDNA) in the nucléus of infected hépatocytes. However, persistent suppression of HBV DNA slows liver disease progression and helps to 30 prevent hepatocellular carcinoma (HCC).
Current therapy goals for HBV-infected patients are directed to reducing sérum HBV DNA to low or undetectable levels, and to ultimately reducing or preventing the development of cirrhosis and HCC.
Currently, the highest rate of functional cure in HBV occurs following therapy with the immunomodulator Interferon-alpha (IFN-alpha). But even treatment with 48-52 weeks of IFNalpha results in responder rates of about 3-7% durable HBsAg loss at best.
Nevertheless, quantitative HBsAg measurements hâve been associated with response to treatment and hâve been shown to predict response: Low HBsAg titer (around or < 100 lU/ml) at end of treatment with nucleoside or nucléotide inhibitors were associated with response or a lower risk of relapse after stopping therapy. In addition, quantitative HBsAg has also been shown to predict response to IFN-alpha treatment.
Consequently, décliné or loss of HBsAg is used as predictor for functional cure and implemented in the international EASL F1BV treatment guideline (EASL clinical practice guidelines April 2017).
There is a need to develop new strategies of treating HBV-infections and/or to achieve a functional cure in chronically HBV-infected individuals. This objective is addressed in the présent invention using the best experimental animal model system to examine immunemediated functional cure of HBV, i.e., woodchucks chronically infected with woodchuck hepatitis virus (WHV).
Summary of the invention
Provided herein are combination products and methods for the treatment of HBV infection in a subject in need thereof. The subject matter of the invention is disclosed in the following embodiments.
Subject-matter of the invention is a composition comprising Parapoxvirus ovis selected from the group comprising:
- optionally mactivated Parapoxvirus ovis (PPVO) virions and/or active fragments thereof, and/or
- nucleic acid vectors or synthetic nucleic acid molécules expressing PPVO and/or at least one active fragment thereof, and/or
- cells comprising PPVO virions or fragments thereof and/or nucleic acid vectors and/or synthetic nucleic acid molécules expressing PPVO and/or at least one active fragment thereof, for use in combination with at least one different antiviral drug for the treatment of an individual with a Hepatitis B Virus (HBV) infection.
As used herein, it is possible to first use either the at least one antiviral drug (e.g., a nucleoside/nucleotide analogue, such as Entecavir, Tenofovir, etc.) or to use PPVO first, and subsequently (secondly) treat the individual in need thereof with PPVO in combination with the at least one additional antiviral drug, and further subsequently (thirdly) continue the treatment with PPVO as disclosed herein either for a short period (days to weeks) or for months or even years ad infinitum as maintenance therapy. Altematively, the treatment may be continued with at least one antiviral drug. Additionally, the combination treatment according to the présent invention may be repeated as required, e.g. at least once, twice, three times, etc.. In addition, combination therapy can be started at the same time and / or stopped at the same time.
Subject-matter of the invention is the composition comprising Parapoxvirus ovis selected from the group comprising:
- optionally inactivated Parapoxvirus ovis (PPVO) virions and/or active fragments thereof, and/or
- nucleic acid vectors or synthetic nucleic acid molécules expressing PPVO and/or at least one active fragment thereof, and/or
- cells comprising PPVO virions or fragments thereof and/or nucleic acid vectors and/or synthetic nucleic acid molécules expressing PPVO and/or at least one active fragment thereof, for use in combination with at least one different antiviral drug for the treatment of an individual with a Hepatitis B Virus (HBV) infection in accordance with the preceding embodiment, wherein the different antiviral drug is an anti-HBV antiviral drug.
Subject-matter of the invention is the composition comprising Parapoxvirus ovis (PPVO) for use in combination with at least one different antiviral drug for the treatment of an individual with a Hepatitis B Virus (HBV) infection in accordance with the above embodiments of the invention, wherein the PPVO is a recombinant virus nucleic acid or at least one active fragment thereof, and/or wherein the PPVO is a recombinantly produced virion and/or at least one active fragment thereof.
Subject-matter of the invention is the composition comprising Parapoxvirus ovis (PPVO) for use in combination with at least one different antiviral drug for the treatment of an individual with a Hepatitis B Virus (HBV) infection according to any one of the preceding embodiments, wherein the PPVO is selected from the group of PPVO strains comprising NZ2, NZ7, NZ10, D1701, OV/20, OV/7, OV/C2, OV/mi-90, OV-Torino, SA00, Bo29, orfll, Greek orf strain 155, and/or Greek orf strain 176, or a taxonomically related Parapoxvirus ovis orf strain.
Subject-matter of the invention is the composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of the preceding embodiments, wherein the antiviral drug is selected from the group of drugs comprising nucleotide/nucleoside analogues as active ingrédients, Capsid assembly inhibitors or modulators, capsid / core inhibitors or modulators, encapsidation inhibitors or modulators, RNAi, Therapeutic vaccination, Toll-like-receptor (TLR) agonists and -antagonists, epigenetic modifiers, entry inhibitors or modulators, cyclophilin inhibitors or modulators, Inhibitors of HBsAg sécrétion, HBsAg inhibitors, HBV entry inhibitors or modulators, cccDNA inhibitors, immunomodulators (Interferons and other cytokines), and/or check-point inhibitors (e.g. PD-1 ).
Subject-matter of the invention is the composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of the preceding embodiments, wherein the group of drugs comprising nucleotide/nucleoside analogues as active ingrédients comprises Tenofovir, Tenofovir disoproxil fumarate (TDF), Tenofovir-Alafenamid (TAF), Entecavir, Lamivudine, Telbivudine, Adefovir, Emtricitabine and/or Clevudine.
Subject-matter of the invention is the composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of the preceding embodiments, wherein PPVO and the at least one different antiviral drug are formulated for separate/subsequent administration, or wherein the PPVO and the at least one different drug as defined in any of the preceding embodiments are formulated for concomitant/simultaneous administration.
Subject-matter of the invention is the composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of the preceding embodiments, wherein PPVO and the at least one different antiviral drug are formulated for separate/subsequent administration, or wherein the PPVO and the at least one different drug as defined in any of the preceding embodiments s are formulated for concomitant/simultaneous administration.
Subject-matter of the invention is the composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of the preceding embodiments, wherein the PPVO and the at least one different antiviral drugs are provided as single drug units or combination products selected from the group comprising: tablets, capsules, lozenges, particularly acid-resistant capsules, drops, patches, depot administration forms, solutions, solutions for injection, solution for infusion, dilutions, creams, ointments, salves, powders, powder for reconstitution, powder for reconstitution and infusion, and/or sprays.
Subject-matter of the invention is the composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of the preceding embodiments, wherein said individual is selected from the group of patients with acute HBV infection, chronic HBV infection, patients with détectable HBsAg, patients with détectable HBV RNA, patients with détectable HBV DNA, patients with détectable cccDNA, patients with liver inflammation, patients with liver steatosis, patients with liver fibrosis, patients with liver cirrhosis, patients with liver cancer, patients with hepatocellular carcinoma, acutely or asymptomatically or chronically infected patients, patients subjected to antiviral treatment , patients that do not respond to antiviral treatment with antiviral drugs 5 according to any one of the preceding embodiments, or patients that hâve acquired résistance to at least one antiviral drug, and/or patients that are co-infected with at least one additional pathogenic virus selected from the group comprising deltavirus, retroviridae, herpesviridae, poxviridae, parvoviridae , adenoviridae, picomaviridae, hepadnaviridae, flaviviridae, orthomyxoviridae, paramyxoviridae, papovaviridae, polyomaviridae, rhabdoviridae, 10 coronaviridae, bunyaviridae, arenaviridae, reoviridae, and togaviridae.
Subject-matter of the invention is the composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of the preceding embodiments, wherein the dose of PPVO is in the range of 15 1 x 106 - 1 x 1010 viral particles and the dose of the at least one different antiviral drug is selected according to the manufacturer’s instructions.
Subject-matter of the invention is the composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection as 20 defined in the preceding embodiments, wherein PPVO and the at least one different antiviral drug are administered for < 72 weeks, preferably < 60 weeks, more preferably < 48 weeks, < 36 weeks, < 24 weeks, <12 weeks, <6 weeks, < 4 weeks, < 2 weeks, or <1 week.
Subject-matter of the invention is the composition according to any of the preceding 25 embodiments for use in combination with at least one different antiviral drug for the treatment of an individual with HBV infection according to any one of the preceding embodiments, wherein the PPVO is inactivated.
Subject-matter of the invention is the composition comprising PPVO for use in combination with 30 at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of the preceding embodiments, wherein the at least one different antiviral drug is Entecavir.
Subject-matter of the invention is the composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a ElBV infection according to any one of the preceding embodiments, wherein the patient treated with said composition and with at least one different antiviral drug is a patient that is HBsAg and/or HBeAg positive, and wherein the HBsAg and/or HBeAg load is reduced or HBsAg and/or HBeAg loss occurs over the course of the treatment as defined in any of the foregoing embodiments.
Subject-matter of the invention is the composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of the preceding embodiments, wherein the composition is formulated for intravenous, intramuscular, oral, parentéral, intradermal, and/or subcutaneous administration.
Subject-matter of the invention is a method of treatment of a HBV-infected patient in need thereof with an effective amount of PPVO and an effective amount of at least one different antiviral drug, wherein the PPVO is selected from the group comprising:
- optionally inactivated Parapoxvirus ovis (PPVO) virions and/or active fragments thereof, and/or
- nucleic acid vectors or synthetic nucleic acid molécules expressing PPVO and/or at least one active fragment thereof, and/or
- cells comprising PPVO virions or fragments thereof and/or nucleic acid vectors and/or synthetic nucleic acid molécules expressing PPVO and/or at least one active fragment thereof.Subject-matter of the invention is the method of treatment according to the preceding embodiment, wherein the PPVO is a recombinant virus nucleic acid or at least one active fragment thereof, and/or wherein the PPVO is a recombinantly produced virion and/or active fragments thereof.
Subject-matter of the invention is the method according to the preceding embodiments, wherein the different antiviral drug is selected from wherein the antiviral drug is selected from the group of drugs comprising nucléotide analogues as active ingrédients, Capsid assembly inhibitors or modulators, capsid / core inhibitors or modulators, encapsidation inhibitors or modulators, RNAi, Therapeutic vaccination, Toll-like-receptor (TLR) agonists and -antagonists, epigenetic modifiers, entry inhibitors or modulators, cyclophilin inhibitors or modulators, Inhibitors of HBsAg sécrétion, HBsAg inhibitors, HBV entry inhibitors or modulators, cccDNA inhibitors, immunomodulators (e.g., Interferons and other cytokines), and/or check-point inhibitors (e.g. PD-1 ),
Subject-matter of the invention is the method according to any one of the preceding embodiments, wherein the group of drugs comprising nucleotide/nucleotides analogues as active ingrédients comprises Tenofovir, Tenofovir disoproxil fumarate (TDF), Tenofovir-Alafenamid (TAF), Entecavir, Lamivudine, Telbivudine, Adefovir, Emtricitabine, and/or Clevudine.
Subject-matter of the invention is the method according to any one of the preceding embodiments, wherein the antiviral drug is Entecavir.
Subject-matter of the invention is the method according any one of the preceding embodiments, wherein PPVO and the at least one different antiviral drug are separately/separately administered.
Subject-matter of the invention is the method according any one of the preceding embodiments, wherein PPVO and the at least one different antiviral drug are concomitantly/simultaneously administered.
Subject-matter of the invention is the method according any one of the preceding embodiments, wherein PPVO and the at least one different antiviral drug is provided in separate single unit form or as a combination products selected from the group comprising: tablets, capsules, lozenges, particularly acid-resistant capsules, drops, patches, depot administration forms, solutions, solutions for injection, solution for infusion, dilutions, creams, ointments, salves, powders, powder for reconstitution, powder for reconstitution and infusion, and/or sprays.
Subject-matter of the invention is the method according any one of the preceding embodiments, 5 wherein PPVO and/or the at least one different antiviral drug are formulated for intravenous, intramuscular, oral, parentéral, topical, intradermal, and/or subcutaneous administration.
Subject-matter of the invention is the method according to any one of the preceding embodiments, wherein said individual is selected from the group of patients with acute HBV 10 infection, chronic HBV infection, patients with détectable HBsAg, patients with détectable HBV RNA, patients with détectable HBV DNA, patients with détectable cccDNA, patients with liver inflammation, patients with liver steatosis, patients with liver fibrosis, patients with liver cirrhosis, patients with liver cancer, patients with hepatocellular carcinoma, asymptomatic or acutely or chronically infected patients, patients subjected to antiviral treatment, patients that do 15 not respond to antiviral treatment with antiviral drugs according to any one of the preceding embodiments, or patients that hâve acquired résistance to at least one antiviral drug, and/or patients that are co-infected with at least one additional pathogenic virus selected from the group comprising deltavirus, retroviridae, herpesviridae, , poxviridae, parvoviridae, adenoviridae, picomaviridae, hepadnaviridae, flaviviridae, orthomyxoviridae, paramyxoviridae, papovaviridae, 20 polyomaviridae, rhabdoviridae, coronaviridae, bunyaviridae, arenaviridae, reoviridae, and togaviridae.
Subject-matter of the invention is the method according to any one of the preceding embodiments, wherein the dose of PPVO is in the range of 1 x 106 - 1 x 1010 viral particles, 25 and/or wherein the dose of the at least one different antiviral drug is selected according to the manufacturer’s instructions.
Subject-matter of the invention is the method according to any one of the preceding embodiments, wherein PPVO and the at least one different antiviral drug are administered for < 30 72 weeks, preferably < 60 weeks, more preferably < 48 weeks, < 36 weeks, < 24 weeks, < 12 weeks, <6 weeks, < 4 weeks, < 2 weeks, or <1 week.
Subject-matter of the invention is a method for the réduction of HBV viral load in a HBVinfected patient in need thereof comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method for the réduction of HBsAg load in a HBV-infected patient in need thereof comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method for the réduction of liver damage, liver cirrhosis, and/or liver fibrosis, in a HBV-infected patient in need thereof comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method for inducing liver tissue régénération in a HBVinfected patient in need thereof comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method for reducing side-effects associated with the treatment of a HBV-infected patient, wherein said side-effects are caused by the treatment with interferons and/or nucleotide/nucleoside analogues comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments, in particular the réduction of side-effects selected from the group comprising fever, tissue inflammation, psychological disturbances, and/or hematological disturbances.
Subject-matter of the invention is a method for the réduction of HBeAg load in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter ofthe invention is a method for the restoration and/or réactivation ofthe immune response in a HBV-infected patient in need thereof comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method of reducing the amount of HBV DNA, eliminating HBV DNA and/or silencing HBV DNA, in particular cccDNA in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method of preventing the de novo formation of cccDNA in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method of inhibiting or reducing the expression of HBV proteins in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method of suppressing réplication of HBV in a HBVinfected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method of éradication of HBV in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method of breaking immunological tolérance towards HBV infections in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method of breaking tolérance towards HBsAg and/or HBeAg in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method of inducing HBsAg-specific antibodies in a HBVinfected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method of inducing HBeAg-specific antibodies in a HBVinfected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method of slowing down or inhibiting the progression of steatosis in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing embodiments.
Subject-matter of the invention is a method according to any one of the preceding embodiments, wherein PPVO and the at least one different antiviral drug are administered for < 72 weeks, preferably < 60 weeks, more preferably < 48 weeks, < 24 weeks, < 12 weeks, <6 weeks, < 4 weeks, < 2 weeks, or <1 week.
Subject-matter of the invention is a médicinal kit product comprising a first container comprising a pharmaceutical compositions comprising PPVO, preferably inactivated PPVO, and a second container comprising a pharmaceutical compositions comprising at least one different antiviral drug as defined in any one of the preceding embodiments or a pharmaceutical composition comprising PPVO, preferably inactivated PPVO, and at least one different antiviral drug as defined in any one of the preceding embodiments in form of a combined formulation, and optionally instructions for use, pharmaceutically acceptable media for reconstitution, syringes, and/or microneedles, etc.
Subject-matter of the invention is a médicinal kit product according to the preceding embodiment, wherein the compositions comprising PPVO, preferably inactivated PPVO, and the pharmaceutical composition comprising at least one different antiviral drug are formulated as tablets, capsules, lozenges, particularly acid-resistant capsules, drops, patches, depot 5 administration forms, solutions, solutions for injection, solution for infusion, dilutions, creams, ointments, salves, powders, powder for reconstitution, powder for reconstitution and infusion, and/or sprays, etc..
Experiments
In the woodchuck animal model of chronic hepatitis B, intramuscular treatment with the immunomodulator AIC649 for 8 weeks has been shown to induce a unique bi-phasic response pattern, with réduction of woodchuck hepatitis virus (WHV) DNA and surface antigen (WHsAg) (Paulsen et al. (2015)).
In the présent example, the antiviral activity of AIC649, alone or in combination with Entecavir (ETV), as well as different dosing routes and longer treatment periods were explored in the woodchuck. The objective was to further explore the safety and potential of AIC649 to induce a functional cure in chronic hepatitis B virus infection.
In woodchucks, over a 36-week period, AIC649 was administered intravenously and then intramuscularly, alone or in combination with an initial 12 weeks of the direct acting antiviral, ETV, given orally. The efficacy of AIC649 monotherapy, ETV monotherapy, or combination AIC649 + ETV therapy was compared to a placebo control group.
Treatment-induced changes in viremia, antigenemia, immunological parameters, as well as the induction of WHsAg antibody séroconversion were evaluated for détermination of antiviral effects. Daily observations, changes in body weight and body températures, changes in hematology and clinical chemistry, as well as necropsy and histopathology were assessed for 30 détermination of safety.
The bi-phasic response pattern induced by AIC649 monotherapy previously observed was confirmed. Treatment with AIC649 alone already led to a clear réduction of WHV DNA as well as WHsAg from pretreatment levels. A significant and even stronger and sustained antiviral effect was observed in the AIC649 + ETV combination group: WHV DNA and WHsAg stayed markedly suppressed or even undetectable for several months. Cell mediated immune responses, as well as anti-WHsAg antibody response, were observed in the two groups receiving AIC649 but not in the ETV monotherapy group. The changes in the liver disease markers were comparable between the groups, but the progression of steatosis during the study appeared slower in the AIC649 alone and the AIC649 + ETV combination group. The observed sustained loss of WHsAg and the induction of anti-WHsAg antibodies accompanied by cell mediated immune responses support the hypothesis that AIC649 induces a physiologically “concerted”, reconstituted immune response to WHV. AIC649 as a combination partner to ETV dramatically increases the efficacy of treatment. AIC649’s potential for inducing a functional cure in HBVinfected patients is surprisingly supported by this preclinical study.
Experiment 1
In the présent study, the antiviral activity of AIC649, alone or in combination with Entecavir (ETV), as well as different dosing routes and longer treatment periods were explored in chronically WHV-infected woodchucks. The objective was to further explore the safety and potential of AIC649 to induce a functional cure in chronic hepatitis B virus infection.
Methods
In woodchucks, over a 36-week period, AIC649 was administered i.v. and then i.m., alone or in combination with an initial 12 weeks of the direct acting antiviral, ETV, given orally. See Figure 1 : Study design
The efficacy of AIC649 monotherapy, ETV monotherapy, or combination AIC649 + ETV therapy was compared to a placebo control group (N = 5 animais / group). Treatment induced changes in viremia, antigenemia, immunological parameters, as well as the induction of WHsAg antibody séroconversion were evaluated for détermination of antiviral effects. Daily observations, changes in body weight and body températures, changes in hematology and clinical chemistry, as well as necropsy and histopathology were assessed for détermination of safety.
Animais
Ail 20 woodchucks (10 males, 10 females) used in this study were bom in captivity were inoculated at 3 days of âge with the cWHV7P2a inoculum, containing woodchuck hepatitis virus (WHV) strain WHV7-11 (Fletcher et al. (2015): PLOSPath, 11, el005103). Pups inoculated with cWHV7P2a were reared and maintained until they were approximately 15 to 17 months of âge. Woodchucks were housed in pairs or individually and given ad libitum access to food and water throughout the pre-study and study periods. Ail woodchucks received orally, daily 50 mg/kg of fenbendazole (panacur) for 10 days for treatment of possible infection with Giardia. Woodchucks were screened for biochemical and hématologie abnormalities. Woodchucks were also tested for WHsAg, antibodies against WHsAg (anti-WHs) and WHV DNA. Ail woodchucks were confirmed as established chronic carriers of WHV based on accepted criteria developed over the past 30 years of expérience with néonatal experimental infections with WHV (i.e., WHV DNA and WHsAg positive, anti-WHs négative at 9 to 12 months of âge and thereafter). Absence of liver tumors in woodchucks with low sérum gamma-glutamyl transferase (GGT) activity was confirmed by ultrasonography in 16 of the 20 woodchucks received. Three other woodchucks had slightly to moderately elevated sérum GGT activity, but presented without liver tumors during the initial ultrasonography. Ail woodchucks were implanted with microchips (dorsal base of the tail) that had been programmed with the animal identification number (DASHost Software, Biomédical Data Systems Inc.). Animais were manually randomized to 1 of 4 treatment groups, stratified by gender, body weight, pre-treatment sérum markers (WHsAg, WHV DNA levels, anti-WHsAg antibody titers), complété blood counts (CBCs), sérum levels of GGT and sorbitol dehydrogenase (SDH).
AIC649 (and Vehicle AIC)
| AIC649: | Lyophilisate for reconstitution, in glass vials with 1.1 x 109 viral particles (parapox virus ovis (PPVO))/vial, reconstituted in 1.1 mL pyrogen-free water | |
| Vehicle AIC: | Lyophilisate for reconstitution, reconstituted in 1.1 mL pyrogenfree water | |
| Method of administration: | Intravenous or intramuscular | |
| Frequency of administration: | Weeks 1 to 24: twice weekly Weeks 25 to 36: once weekly | |
| Dose levels: | AIC649: 1 x 109 viral particles (PPVO) Vehicle: 0 viral particles (PPVO) | |
| Dose volume: | 1 mL | |
| Duration of treatment | Total: 36 weeks (12 weeks i.v., followed by 24 weeks i.m.) | |
| ETV (and vehicle ETV) | ||
| 5 | Entecavir (ETV): | Powder (Selleckchem (Munich, Germany), suspended in stérile isotonie saline |
| Vehicle ETV: | stérile isotonie saline | |
| Method of administration: | Oral | |
| Frequency of administration: | Week 1 to 12: daily | |
| Dose levels: | ETV: 0.2 mg/kg Vehicle: 0 mg/kg | |
| Dose volume: | 0.2 mL ETV (or vehicle) + 3 to 5 mL woodchuck liquid diet | |
| Duration of treatment | Total: 12 weeks | |
| Animal procedures |
Procedures were performed according to the schedule described in table l :
Table l : Schedule of procedures and assays
| Study phase | Week | Animal procedures | Assays | ||||||
| Body weight & température | Bleed | Liver biopsy | WHV DNA & serologyb | Hematology & biochemistry | aPTT & PT | T cell response' | Cell markers & cytokines0 | ||
| Pretreatment | -2 to-1 | X | X | X | X | X | |||
| Treatment | T=0 | X | X | X | X | X | |||
| 1 | X | X | X | ||||||
| 2 | X | X | X | ||||||
| 3 | X | X | X | ||||||
| 4 | X | X | X | ||||||
| 5 | X | X | X | ||||||
| 6 | X | X | X | X | X | X | X | ||
| 7 | X | X | X | ||||||
| 8 | X | X | X | ||||||
| 9 | X | X | X | ||||||
| 10 | X | X | X | ||||||
| 11 | X | X | X | ||||||
| 12 | X | X | X | X | X | X | X | X | |
| Treatment (2x/week) | 13 | X | X | X | |||||
| 14 | X | X | X | ||||||
| 15 | X | X | X | ||||||
| 16 | X | X | X | X | X | ||||
| 17 | X | X | X | ||||||
| 18 | X | X | X | ||||||
| 19 | X | X | X | ||||||
| 20 | X | X | X | ||||||
| 21 | X | X | X | X | X | X | X | ||
| 22 | X | X | X | ||||||
| 23 | X | X | X | ||||||
| 24 | X | X | X | X | X | X | X | X | |
| Treatment (Ix/week) | 25 | X | |||||||
| 26 | X | X | X | ||||||
| 27 | X | ||||||||
| 28 | X | X | X |
| Study phase | Week | Animal procedures | Assays | |||||
| Body weight & température | Bleed | Liver biopsya | WHV DNA & serology6 | Hematology & biochemistry | aPTT & PT | T cell response' | Cell markers & cytokinesd | |
| 29 | X | |||||||
| 30 | X | X | X | X | X | X | X | |
| 31 | X | |||||||
| 32 | X | X | X | |||||
| 33 | X | |||||||
| 34 | X | X | X | |||||
| 35 | X | |||||||
| 36 | X | X | X | X | X | X | X | X |
aPTT=activated partial thromboplastin time; DNA=deoxyribonucleic acid; PT=prothrombin time; WHV=woodchuck hepatitis virus
a) Liver biopsy analysis included: WHV DNA RI, WHV cccDNA, WHV RNA (Southern and Northern blots), histology, WHcAg, WHsAg, anti-WHsAg-Ab
b) DNA and serology included: WHV DNA (Slot blot & PCR), WHsAg, anti-WHsAg-Ab
c) T cell responses determined following stimulation of PBMCs with peptides covering entire WHsAg, WHcAg, WHVxAg
d) Samples stored at -80°C for analysis of cell différentiation markers and cytokines.
• Mortality was assessed daily for ail animais.
• Body weight/temperature and clinical signs were assessed weekly.
• Blood samples were taken for serology during the pre-treatment period, weekly from randomization (TO) to Week 24 and every second week from Week 25 to Week 36.
· Blood samples were taken for hematology and clinical chemistry during pre-treatment, at
TO, and at Weeks 4, 8, 12, 16, 21, 24, 30 and 36.
• Blood samples were taken for aPTT and PT assessment at TO, and Weeks 12, 21, 24, 30, and 36.
• Blood samples were taken for assessment of T-cell responses at TO, and Weeks 6, 12, 21, 10 24, 30 and 36.
• Blood samples were taken for assessment of cell différentiation markers and cytokine measurement during pre-treatment and at Week 6, 12, 21, 24, 30, and 36. Blood collection during the treatment period was performed approximately 16 hours after the administration of “Vehicle ETV”, “Vehicle AIC”, ETV, and/or AIC649 · Liver biopsies were taken during the 2-week pre-treatment period, and at Weeks 6, 12, 16,
24, and 36.
Timing of blood sampling during the treatment period
Blood samples for analysis of cytokine and cellular markers were taken approximately 16 h post-treatment.
Blood samples for analysis of serology, virology, hematology (including aPTT and PT) or clinical chemistry, and T-cell responses were taken approximately 0.5 to LO h after oral 25 dosing (ETV / Vehicle ETV) and prior to i.v. dosing (AIC649 / Vehicle AIC) to allow blood collection and iv dosing to be performed during the same anesthésia event. For intravenous injections of AIC649 or Vehicle AIC, animais were anesthetized using ketamine/xylazine i.m. injection, 10:1 mixture, 25 to 50 mg/kg ketamine/1.0 to 5.0 mg/kg xylazine, and/or isoflurane inhalation (ie, 1 to 3% via nose cône). Intramuscular injections of AIC649 or AIC Vehicle 30 were performed without anesthésia..
Clinical observations and laboratory investigations
Clinical observations signs
Mortality
Mortality was assessed daily for ail animais.
Body température and weight
Body température and weight assessments were performed together, weekly. The animal identification number and body température were read from a microchip implanted in the 5 dorsal base of the tail using a hand-held chip reader (Biomédical Data Systems Inc.). Data were reported as individual values and summarized by group as mean ±SD.
Hematology
Uncoagulated whole blood was collected in EDTA tubes. Samples were shipped on cold packs for same-day delivery to a laboratory for analysis. Samples were analyzed the following day using an automated cell counter system (coulter) with program settings for woodchucks (Bellezza, C.A., et al., 2002, Elsevier. p. 309-328.).
Complété blood counts included the following parameters:
White blood cells (WBC) Segmented Neutrophils Banded Neutrophils Lymphocytes Monocytes Eosinophils Basophils
Red blood cells (RBC) Hemoglobin (Hb)
Hematocrit (Hct)
Mean cell volume (MCV)
Mean cell hemoglobin (MCH)
Mean cell hemoglobin concentration (MCHC)
Red cell distribution width (RDW)
Platelet count (PLT)
Mean platelet volume (MPV)
Réticulocytes (RETI)
Clinical chemistry
Sérum was collected and frozen for shipping on dry ice within the sample week. Samples were thawed once for analysis. aPTT and PT were determined on citrate plasma. Samples were analyzed using an autoanalyzer (Hitachi) using established clinical chemistry assays for woodchucks (Peek, S.F., et al.: Hepatology, 2001. 33(1): p. 254-66) .
The following clinical chemistry parameters were assessed:
Alanine aminotransferase (ALT) Aspartate aminotransferase (AST) Sorbitol dehydrogenase (SDH) Alkaline phosphatase (ALP) Gamma-glutamyltransferase (GGT) Glutamate dehydrogenase (GLDH) Sodium
Potassium
Chloride
Bicarbonate
Anion gap (AG)
Na/K ratio
Urea
Créatinine
Calcium
Phosphate Magnésium
Total protein (TP)
Albumin
Globulin
Albumin / globulin ration (A/G ratio)
Activated partial thromboplastin time (aPTT)
Prothrombin time (PT)
Glucose
Total bilirubin (T. bili)
Direct bilirubin (D. bili)
Indirect bilirubin (In. bili)
Amylase
Cholestérol
Creatine kinase (CK)
Iron (Fe)
Total iron binding capacity (TIBC) % saturation (of ferritin)
Lipemia
Hemolysis
Icterus
Histopathology
Tissues from animais terminated were fixed in 10%phosphate buffered formalin and sent for histopathological assessment.
A sélection of the organ and tissue samples collected and fixed at necropsy were processed, wax paraffin embedded, eut at a nominal thickness of approximately 2 to 4 micrometers, and stained with hematoxylin and eosin. The slides were processed and stained and were examined by light microscope.
Organs assessed
The following organs were collected for histologicai assessment:
adrenal glands, aorta, bone (fémur) and articulation, bone (sternum) with bone marrow, bone marrow smears (fixed in methanol and stained by May Grünwald-Giemsa method), brain, bronchi (mainstem), caecum, colon, duodénum, epididymides, eyes, gallbladder, heart, ileum, injection site(s) (a sample was taken from the area injected), jéjunum, kidneys and ureters, 20 larynx, liver, lungs, lymph node (mandibular), lymph node (mesenteric), mammary gland, oesophagus, optic nerves, ovaries and oviducts, pancréas, parathyroid glands, Peyer's patches, pituitary gland, prostate, rectum, salivary glands (mandibular, parotid, sublingual), sciatic nerves, séminal vesicles, skeletal muscle, skin, spinal cord (cervical, thoracic, lumbar), spleen, stomach, testes, thymus, thyroid glands, tongue, trachea, ureters, urinary bladder, utérus (homs + cervix), vagina, ail gross lésions.
Effïcacy/virological assessments
WHV antigen/antibodies in sérum
Sérum WHV DNA
WHV DNA levels in sérum were quantified as genomic équivalents (ge’s) using slot-blot hybridization with a standardized 32P-labelled WHV DNA fragment probe on a nitrocellulose membrane. The Lower Limit Of Quantification (LLOQ) ofthe assay was approximately 107 ge/mL sérum. Samples below the slot-blot LLOQ were also assessed using a quantitative realtime PCR assay (Menne, S., et al., Antimicrob Agents Chemother, 2008. 52(10): p. 3617-32) with an LLOQ approximately 5.0 to 7.0 x 102 WHV ge/mL sérum.
Sérum WHsAg
WHsAg levels in sérum were quantified using an established ELISA with an LLOQ of approximately 5 ngWHsAg/mL sérum (Cote, P.J., et al., Viral Immunol, 1993. 6(2): p. 1619)·
Sérum anti-WHs antibodies
Anti-WHs antibody levels in sérum were quantified using an established ELISA technique (Cote, P.J., et al., Viral Immunol, 1993. 6(2): p. 161-9). The LLOQ of the assay using a 1:100 sample dilution was approximately 100 StdU/mL sérum. Samples were graded as follows:
• 100 to 200 StdU/mL were considered trace levels • 200 to 300 StdU/mL were considered very low levels • 300 to 500 StdU/mL were considered low levels • 500 to 2000 StdU/mL were considered moderate levels • >2000 StdU/mL were considered high levels (e.g. as might be expected after 3-fold immunization of naïve woodchucks with WHsAg-alum vaccine)
Care should be taken interpreting the results from this assay since in untreated chronically infected animais, there is a considérable excess of circulating WHsAg, making détection of unbound anti-WHs Ab unlikely. Therefore, négative results for anti-WHsAg détection demonstrate a lack of unbound WHs-specific antibody, not a lack of total WHs-specifîc antibody.
T-cell proliférative responses
PBMCs were isolated from whole blood and cultured for 5 days in the presence of DMSO (négative control), lipopolysaccharide (LPS, positive control), recombinant human IL-2 (positive control), or pools of peptides covering the entire WHcAg, WHsAg, or WHxAg, respectively. Using the CellTiter-Glo® assay, the number of viable cells in each test well was 10 assessed using a luminescent signal proportional to the amount of ATP présent, and thus to the number of viable cells. Cultures were assessed after 5 days and a stimulation index (SI) was derived relative to the négative Controls as a measure of T-cell responses to spécifie antigens/stimuli:
SI = Test luminescence / négative control luminescence 15
Cytokines and cell markers
Immune responses associated with treatment were determined by changes in RNA transcript levels of IFN-a, IFN-γ, TNF-a, interleukin 6 (IL-6), CD3, CD4, CD8, CD 14, CD56, and 20 CD79B in blood and liver using PCR. Briefly, whole blood was collected into PAXgene blood tubes (Qiagen, Redwood City, CA) at time points indicated above. Samples were stored at -70°C until use. Total RNA was further isolated from liver biopsy samples collected as indicated above using the RNeasy Mini Kit (Qiagen) with on-column DNase I digestion using RNase-Free DNase (Qiagen).
Following reverse transcription of mRNA with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) using oligo(dT), complementary (c) DNA samples were amplified on a 7500 Real Time PCR System instrument (Applied Biosystems) using TaqMan Gene Expression Master Mix (Applied Biosystems) and woodchuck-specific primers 30 and probes (Table 2). Woodchuck 18S rRNA expression was used to normalize target gene expression. Transcription levels of target genes were calculated as a fold-change relative to pretreatment level at week -1 (liver) or at T0 (blood) using the formula 2Δα.
Table 2: Oligonucleotides used for analyses of gene expression in blood and liver
| Gene | Primers and Probe | Sequence |
| IFN-a | F (SEQ IDNO: 1) | 5’- CTCAAGCTGTTGCTGTCCTC -3’ |
| R (SEQ ID NO: 2) | 5’- CTTCTGGGTGCTGAAGAGGT -3’ | |
| P (SEQ ID NO: 3) | 5’- CCAGATGACCCAGCAGATCCTCA -3’ | |
| IFN-γ | F (SEQ ID NO: 4) | 5'- ATCCAAAGGAGCATGGACAC -3' |
| R (SEQ ID NO: 5) | 5'- TGAACTTGAGACACCTTTAGGAA -3' | |
| P (SEQ ID NO: 6) | 5'- CAACAGCAGTACCAATAAGCTGCAGGA -3' | |
| TNF-a | F (SEQ ID NO: 7) | 5'- CCTGCAAACGGGCTATACCTT -3' |
| R (SEQ ID NO: 8) | 5'- GTGTGGGTGAGGAGCACGTA -3' | |
| P (SEQ ID NO: 9) | 5'- CAGCCTTGGCCCTTGAAGAGGACCT -3' | |
| IL-6 | F (SEQ IDNO: 10) | 5'- CCATGCAACTCATCTTGAGC -3’ |
| R (SEQ IDNO: 11) | 5'- ATGCCCATGAACCAATAAGC -3' | |
| P (SEQ IDNO: 12) | 5'- ATTTCCTGCAGTTCACCC -3' | |
| CD3 | F (SEQ IDNO: 13) | 5'- CGGAGTTCGCCAGTCAAGA -3' |
| R(SEQ IDNO: 14) | 5'- TTGGTGGTTTCCTTGAAGACG -3' | |
| P (SEQ IDNO: 15) | 5’- CTTCAGACAAGCAGACTCTGTTGCCCAA -3' | |
| CD4 | F (SEQ IDNO: 16) | 5’- AGGTCTCAAAGCCCGAGAAGA -3’ |
| R (SEQ IDNO: 17) | 5’- GTAGGCACTGCCACATCCCT -3’ | |
| P (SEQ IDNO: 18) | 5’- ATTCGGGTGCCAAACCCCAAGG -3’ | |
| CD8 | F (SEQ IDNO: 19) | 5’-TGGACTTCGCCTGTGATATCTAC -3’ |
| R (SEQ ID NO: 20) | 5’- GTTTCCGGTGGTGACAGATGA -3’ | |
| P (SEQ ID NO: 21) | 5’- TGCGCGGTCCTTCTGTTGTCACTG -3’ | |
| CD14 | F (SEQ ID NO: 22) | 5 ’ -AA ACTCCCTGGATCTGTC ATTT-3 ’ |
| R (SEQ ID NO: 23) | 5 ’ -CTGACCGTGGCTTCCTATTT-3 ’ | |
| P (SEQ ID NO: 24) | 5 ’ -TCCCTTAGGC ACTTGCTCC AACC-3 ’ | |
| CD56 | F (SEQ ID NO: 25) | 5 ’ - AA ACC ATGACGGAGGGAA AC-3 ’ |
| R (SEQ ID NO: 26) | 5 ’-GACTCCGACTTTGCTTCTACAG-3 ’ | |
| P (SEQ ID NO: 27) | 5 ’-AC ACAGAACCCAATGAGACCACG-3 ’ | |
| CD79B | F (SEQ ID NO: 28) | 5'- ACCCTCCTCATCATCCTCTT -3' |
| R (SEQ ID NO: 29) | 5'- CAATGTCCAGGCCCTCATAG -3' | |
| P (SEQ ID NO: 30) | 5’- ATCGTGCCCATCTTCCTGTTGCT -3’ | |
| 18SrRNA | F (SEQ ID NO: 31) | 5’- GTAACCCGTTGAACCCCATT-3’ |
| R (SEQ ID NO: 32) | 5’- GGGACTTAATCAACGCAAGC-3’ | |
| P (SEQ IDNO: 33) | 5’- GCAATTATTCCCCATGAACG-3’ |
F: forward primer; R: reverse primer; P: probe.
Liver biopsy
Ultrasound-guided liver punch biopsies were performed on anesthetized animais using 16gauge disposable biopsy needle kit mounted on an imaging manifold attached to an 5 ultrasound instrument. At each sampling, 2 to 3 cores, each 16-gauge x 1 to 2 cm were obtained. After the biopsy was taken, animais were prophylactically treated i.m. with longacting benzathine penicillin.
Viral nucleic acids
Liver biopsies were quantitatively analyzed for WHV DNA RI, WHV cccDNA, and WHV RNA (Southern and Northern blot hybridization) as described in the literature (Menne, S., et al., Antimicrob Agents Chemother, 2008. 52(10): p. 3617-32.
Disease progression
Biopsies were assessed for liver disease progression (histology) using criteria developed for woodchuck liver sections (Peek, S.F., et al., Hepatology, 2001. 33(1): p. 254-66. Tennant, B.C., et al.. Hepatology, 1998. 28(1): p. 179-91.) as well as using the METAVIR scale for 20 scoring human liver samples. In addition, Formalin-fixed, paraffin-embedded sections stained with H&E were assessed.
Immunohistochemistry
WHcAg and WHsAg expression (immunohistochemistry) was assessed in liver biopsy samples. Formalin-fixed, paraffin-embedded sections were prepared and stained as described in the literature (Peek, S.F., et al., Hepatology, 2001. 33(1): p. 254-66. Tennant, B.C., et al.. Hepatology, 1998. 28(1): p. 179-91. Cote, P.J., et al. Hepatology, 2000. 31(1): p. 190-200) and assessed.
Statistical analysis
Intergroup statistical comparisons were performed for the following parameters: mean body weights, body températures, viral serological and hepatic parameters, hematology parameters, 5 clinical chemistries, PBMC proliférative responses, and liver histology and immunohistochemistry scores.
Results from woodchucks treated with AIC649 plus ETV (Group 4) were compared to the values at TO or pretreatment, and also to those of woodchucks treated with “Vehicle AIC” 10 plus “Vehicle ETV” (Group 1), with AIC649 plus “Vehicle ETV” (Group 2), and with “Vehicle AIC” plus ETV (Group 3) by using unpaired Student’s t-test with equal variance.
Where indicated, for géométrie means, the log-transformed data for sérum WHV DNA and sérum WHsAg were calculated and averaged arithmetically and tested using Student’s t-test. 15 P values <0.05 were considered statistically significant.
Results
The bi-phasic response pattern induced by AIC649 monotherapy previously observed 20 (Paulsen et al. (2015): PLOSOne, 10, e0144383) was confirmed. Treatment with AIC649 alone already led to a clear réduction of WHV DNA as well as WHsAg from pretreatment levels. A significant and surprisingly even stronger and sustained antiviral effect was observed in the AIC649 + ETV combination group: WHV DNA and WHsAg stayed markedly suppressed or even undetectable for several months in responding animais (Fig 2 25 and 3). Cell mediated immune responses (Fig 4), as well as anti-WHsAg antibody response (Fig 5), were observed in the two groups receiving AIC649 but not in the ETV monotherapy group. The changes in most of the liver disease markers were comparable between the groups, but the progression of steatosis and the increases in GGT (Fig 6) during the study appeared slower in the AIC649 alone and the AIC649 + ETV combination group. Analyses of 30 immunological parameters revealed that AIC649 treatment induces cytokines and cell markers in the liver of chronic WHV carrier woodchucks (Fig 7). AIC649-treatment was well tolerated.
Brief description of the figures
Figure 1
Study design
Treatment / combination (week 0 -12):
AIC649 or “Vehicle AIC”: i.v. treatment, twice a week for 12 weeks
ETV or “Vehicle ETV”: once daily treatment, p.o., for 12 weeks
Maintenance:
Week 13 - 24: AIC649 or “Vehicle AIC”: i.m. treatment, twice a week for 12 weeks Week 25 - 36: AIC649 or “Vehicle AIC”: i.m. treatment, once a week for 12 weeks
ETV= Entecavir
Figure 2
The combination of AIC649 with Entecavir leads to synergistic réduction of viremia levels in chronic WHV carrier woodchucks. AIC649, ETV or the Vehicle AIC, Vehicle ETV were administered according to the study design. At the indicated time points woodchucks were bled and sérum was subjected to détermination of WHV DNA load. n= 5 / 20 group at start of experiment (deaths in group 1: 1 animal week 21; group 2: 1 animal each week 12, 26; group 3: 1 animal each at week 4, 14, 21, 29; group 4: none). Horizontal dotted line representing the mean viral genome équivalents (ge/ml) of ail groups at TO (6.36 x 1010 viral ge/ml). Vertical dotted Unes at week 0 indicated the start of treatment or changes in treatment regimen (week 12 and 24). (A) Sérum WHV DNA concentrations of individual 25 woodchucks (identified by different symbols) in group 1 (vehicle), (B) group 2 (AIC649 only); (C) group 3 (ETV only), (D) group 4 (ETV+AIC649).
Figure 3
The combination of AIC649 with Entecavir leads to synergistic réduction of antigenemia 30 levels in chronic WHV carrier woodchucks. AIC649, ETV or the Vehicle AIC, Vehicle
ETV were administered according to the study design. At the indicated time points woodchucks were bled and sérum was subjected to détermination of WHsAg load. n= 5 / group at start of experiment (deaths in group 1: 1 animal week 21; group 2: 1 animal each week 12, 26; group 3: 1 animal each at week 4, 14, 21, 29; group 4: none). Horizontal dotted line indicates the détection limit for WHsAg. Vertical dotted lines at week 0 indicated the start of treatment or changes in treatment regimen (week 12 and 24). (A) Sérum WHsAg concentrations of individual woodchucks (identified by different symbols) in group 1 (vehicie), (B) group 2 (AIC649 only); (C) group 3 (ETV only), (D) group 4 (AIC649 + ETV).
Figure 4
Only AIC649 treatment stimulâtes cell mediated immunity in chronic WHV carrier woodchucks - even more pronounced in combination with ETV. AIC649, ETV or the Vehicie AIC, Vehicie ETV were administered according to the study design. At the indicated 10 time points woodchucks were bled and PBMCs were stimulated with WHsAg peptides.
Values were nonnalized to individual baseline at TO and are given as fold change from baseline. n= 5 / group at start of experiment (deaths in group 1: 1 animal week 21; group 2: 1 animal each week 12, 26; group 3: 1 animal each at week 4, 14, 21, 29; group 4: none). Given is the géométrie mean per group. Vertical dotted lines at week 0 indicated the start of 15 treatment or changes in treatment regimen (week 12 and 24). (^* ) group 1 (vehicie), (♦) group 2 (AIC649 only); ( ) group 3 (ETV only), ( ) group 4 (ETV+AIC649).
Figure 5
Only AIC649 treatment stimulâtes development of anti-WHsAg antibodies in chronic 20 WHV carrier woodchucks - even more pronounced in combination with ETV. AIC649,
ETV or the Vehicie AIC, Vehicie ETV were administered according to the study design. At the indicated time points woodchucks were bled and anti-WHs antibody levels in sérum were quantified. Values were normalized to individual baseline at TO and are given in %. n= 5 / group at start of experiment (deaths in group 1: 1 animal week 21; group 2: 1 animal each 25 week 12, 26; group 3: 1 animal each at week 4, 14, 21, 29; group 4: none). Given is the géométrie mean per group. Vertical dotted lines at week 0 indicated the start of treatment or changes in treatment regimen (week 12 and 24). (“O) group 1 (vehicie), (^^) group 2 (AIC649 only); (-♦- ) group 3 (ETV only), (*) group 4 (ETV+AIC649).
Figure 6
AIC649 treatment apprears to slow down increases in GGT in chronic WHV carrier woodchucks. ETV or the Vehicle AIC, Vehicle ETV were administered according to the study design. At the indicated time points woodchucks were bled and GGT levels in sérum 5 were quantified. Values were normalized to individual baseline at TO and are given in %. n= 5 / group at start of experiment (deaths in group 1: 1 animal week 21; group 2: 1 animal each week 12, 26; group 3: 1 animal each at week 4, 14, 21, 29; group 4: none). Given is the géométrie mean per group. Horizontal dotted line indicates the baseline (100%). Vertical dotted lines at week 0 indicated the start of treatment or changes in treatment regimen (week 10 12 and 24). (Ό) group 1 (vehicle), (♦“) group 2 (AIC649 only); (-Φ-) group 3 (ETV only), (-*“) group 4 (ETV+AIC649).
Figure 7
AIC649 treatment, but not placebo treatment, induced IFN-γ in the liver of in chronic 15 WHV carrier woodchucks. AIC649, ETV or the Vehicle AIC, Vehicle ETV were administered according to the study design. Liver biopsies were taken at the indicated time points and subjected to détermination of cytokine transcript levels. Values were normalized to individual baseline at week -L n= 5 / group at start of the experiment (deaths in group 1: 1 animal week 21; group 2: 1 animal each week 12, 26; group 3: 1 animal each at week 4, 14, 20 21, 29; group 4: none). Results were plotted only when at least 3 values per time point were available. In group 2 (ETV only) this was only the case at week -1, therefore, no curve is available for this group. Results are given as mean fold change of the group +/- SEM. Vertical dotted lines at week 0 indicated the start of treatment or changes in treatment regimen (week 12 and 24). (·Ο) group 1 (vehicle), (”♦“) group 2 (AIC649 only); ( ) group 3 (ETV only), ( ) group 4 (ETV+AIC649).
Conclusion • There were no findings of toxicological relevance associated with AIC649-treatment.
· Treatment with AIC649 enhanced and extended suppression of viral nucleic acids by ETV in the liver and in blood by several months and AIC649 appeared to stimulate immune responses to WHV antigens: Cell mediated immune responses to WHV antigens were detected, as were anti-WHV antibodies and cytokine induction.
• Cell mediated responses to WHsAg correlated with loss or réduction in circulating WHsAg.
• AIC649 alone induced réduction of WHsAg despite apparently minor réductions in circulating WHV DNA level.
• AIC649 treatment led to sustained loss of hepatic WHc or WHs antigen expression which was more frequent and more pronounced in combination with ETV, but did not occur without 5 AIC649 treatment.
• Virological parameters such as WHV DNA and WHsAg indicated a possible synergistic interaction between AIC649 and ETV.
The observed sustained loss of WHsAg and the induction of anti-WHsAg antibodies 10 accompanied by cell mediated immune responses support the hypothesis of AIC649 inducing a physiologically “concerted”, reconstituted immune response to WHV. AIC649 as a combination partner to ETV dramatically increases the efficacy of treatment. AIC649’s potential for inducing a functional cure in HBV-infected patients is supported by this preclinical study.
Claims (48)
1. A composition comprising Parapoxvirus ovis selected from the group comprising:
- optionally inactivated Parapoxvirus ovis (PPVO) virions and/or active fragments thereof, and/or
- nucleic acid vectors or synthetic nucleic acid molécules expressing PPVO and/or at least one active fragment thereof, and/or
- cells comprising PPVO virions or fragments thereof and/or nucleic acid vectors and/or synthetic nucleic acid molécules expressing PPVO and/or at least one active fragment thereof, for use in combination with at least one different antiviral drug for the treatment of an individual with a Hepatitis B Virus (HBV) infection.
2. The composition comprising Parapoxvirus ovis selected from the group comprising: - optionally inactivated Parapoxvirus ovis (PPVO) virions and/or active fragments thereof, and/or
- nucleic acid vectors or synthetic nucleic acid molécules expressing PPVO and/or at least one active fragment thereof, and/or
- cells comprising PPVO virions or fragments thereof and/or nucleic acid vectors and/or synthetic nucleic acid molécules expressing PPVO and/or at least one active fragment thereof, for use in combination with at least one different antiviral drug for the treatment of an individual with a Hepatitis B Virus (HBV) infection in accordance with claim 1, wherein the different antiviral drug is an anti-HBV antiviral drug.
3. The composition comprising Parapoxvirus ovis (PPVO) for use in combination with at least one different antiviral drug for the treatment of an individual with a Hepatitis B Virus (HBV) infection in accordance with claim 1 or 2, wherein the PPVO is a recombinant virus nucleic acid or at least one active fragment thereof, and/or wherein the PPVO is a recombinantly produced virion and/or at least one active fragment thereof.
4.
The composition comprising Parapoxvirus ovis (PPVO) for use in combination with at least one different antiviral drug for the treatment of an individual with a Hepatitis B Virus (HBV) infection according to any one of claims 1 to 3, wherein the PPVO is selected from the group of PPVO strains comprising NZ2, NZ7, NZ10, DI701, OV/20, OV/7, OV/C2, OV/mi-90, OV-Torino, SA00, Bo29, orfll, Greek orf strain 155, and/or Greek orf strain 176 or a taxonomically related Parapoxvirus ovis orf strain.
5. The composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of claims 1 to 4, wherein the antiviral drug is selected from the group of drugs comprising nucleotide/nucleoside analogues as active ingrédients, Capsid assembly inhibitors or modulators, capsid / core inhibitors or modulators, encapsidation inhibitors or modulators, RNAi, Therapeutic vaccination, Toll-like-receptor (TLR) agonists and —antagonists, epigenetic modifïers, entry inhibitors or modulators, cyclophilin inhibitors or modulators, Inhibitors of HBsAg sécrétion, HBsAg inhibitors, HBV entry inhibitors or modulators, cccDNA inhibitors, immunomodulators, particularly Interferons and other cytokines, and/or check-point inhibitors, particularly PD-1.
6. The composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of claims 1 to 5, wherein the group of drugs comprising nucleotide/nucleoside analogues as active ingrédients comprises Tenofovir, Tenofovir disoproxil fumarate (TDF), Tenofovir-Alafenamid (TAF), Entecavir, Lamivudine, Telbivudine, Adefovir, Emtricitabine, and/or Clevudine.
7. The composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of claims 1 to 6, wherein PPVO and the at least one different antiviral drug are formulated for separate/subsequent administration, or wherein the PPVO and the at least one different drug as defined in any of the preceding claims are formulated for concomitant/simultaneous administration.
8.
The composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of claims 1 to 6, wherein PPVO and the at least one different antiviral drug are formulated for separate/subsequent administration, or wherein the PPVO and the at least one different drug as defined in any of the preceding claims are formulated for concomitant/simultaneous administration.
9. The composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of claims 1 to 8, wherein the PPVO and the at least one different antiviral drugs are provided as single drug units or combination products selected from the group comprising: tablets, capsules, lozenges, particularly acid-resistant capsules, drops, patches, depot administration forms, solutions, solutions for injection, solution for infusion, dilutions, creams, ointments, salves, powders, powder for reconstitution, powder for reconstitution and infusion, and/or sprays.
10. The composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of claims 1 to 9, wherein said individual is selected from the group of patients with acute HBV infection, chronic HBV infection, patients with détectable HBsAg, patients with détectable HBV RNA, patients with détectable HBV DNA, patients with détectable cccDNA, patients with liver inflammation, patients with liver steatosis, patients with liver fibrosis, patients with liver cirrhosis, patients with liver cancer, patients with hepatocellular carcinoma, acutely or asymptomatically or chronically infected patients, patients subjected to antiviral treatment, patients that do not respond to antiviral treatment with antiviral drugs according to any one of claims 1 to 9, or patients that hâve acquired résistance to at least one antiviral drug, and/or patients that are co-infected with at least one additional pathogenic virus selected from the group comprising deltavirus, retroviridae, herpesviridae, poxviridae, parvoviridae, adenoviridae, picomaviridae, hepadnaviridae, flaviviridae, orthomyxoviridae, paramyxoviridae, papovaviridae, polyomaviridae, rhabdoviridae, coronaviridae, bunyaviridae, arenaviridae, reoviridae, and togaviridae.
11. The composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of claims l to 10, wherein the dose of PPVO is in the range of 1 x 106 - 1 x 1010 viral particles and the dose of the at least one different antiviral drug is selected according to the manufacturer’s instructions.
12. The composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of claims 1 to 11, wherein PPVO and the at least one different antiviral drug are administered for < 72 weeks, preferably < 60 weeks, more preferably < 48 weeks, < 36 weeks, < 24 weeks, <_12 weeks, <6 weeks, < 4 weeks, < 2 weeks, or <1 week.
13. The composition according to any of the preceding claims for use in combination with at least one different antiviral drug for the treatment of an individual with HBV infection according to any one of claim 1 to 12, wherein the PPVO is inactivated.
14. The composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of claim 1 to 13, wherein the at least one different antiviral drug is Entecavir.
15. The composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of claim 1 to 14, wherein the patient treated with said composition and with at least one different antiviral drug is a patient that is HBsAg and/or HBeAg positive, and wherein the HBsAg and/or HBeAg load is reduced or HBsAg and/or HBeAg loss occurs over the course of the treatment as defined in any of the foregoing claims.
16. The composition comprising PPVO for use in combination with at least one different antiviral drug for the treatment of an individual with a HBV infection according to any one of claim 1 to 15, wherein the composition is formulated for intravenous, intramuscular, oral, parentéral, topical, intradermal, and/or subcutaneous administration.
17. A method of treatment of a HBV-infected patient in need thereof with an effective amount of PPVO and an effective amount of at least one different antiviral drug, wherein the PPVO is selected from the group comprising:
- optionally inactivated Parapoxvirus ovis (PPVO) virions and/or active fragments thereof, and/or
- nucleic acid vectors or synthetic nucleic acid molécules expressing PPVO and/or at least one active fragment thereof, and/or
- cells comprising PPVO virions or fragments thereof and/or nucleic acid vectors and/or synthetic nucleic acid molécules expressing PPVO and/or at least one active fragment thereof.
18. The method of treatment according to claim 17, wherein the PPVO is a recombinant virus nucleic acid or at least one active fragment thereof, and/or wherein the PPVO is a recombinantly produced virion and/or active fragments thereof.
19. The method according to claim 17 or claim 18, wherein the different antiviral drug is selected from the group of drugs comprising nucleotide/nucleoside analogues as active ingrédients, Capsid assembly inhibitors or modulators, capsid / core inhibitors or modulators, encapsidation inhibitors or modulators, RNAi, Therapeutic vaccination, Toll-like-receptor (TLR) agonists and -antagonists, epigenetic modifiers, entry inhibitors or modulators, cyclophilin inhibitors or modulators, Inhibitors of HBsAg sécrétion, HBsAg inhibitors, HBV entry inhibitors or modulators, cccDNA inhibitors, immunomodulators, particularly Interferons and other cytokines, and/or check-point inhibitors, particularly PD-1.
20. The method according to any one of claims 17 to 19, wherein the group of drugs comprising nucleotide/nucleoside analogues as active ingrédients comprises Tenofovir, Tenofovir disoproxil fumarate (TDF), Tenofovir-Alafenamid (TAF), Entecavir, Lamivudine, Telbivudine, Adefovir, Emtricitabine, and/or Clevudine.
21. The method according to any one of claims 17 to 20, wherein the antiviral drug is Entecavir.
22. The method according any one of claims 17 to 21, wherein PPVO and the at least one different antiviral drug are separately/sequentially administered.
23. The method according any one of claims 17 to 21, wherein PPVO and the at least one different antiviral drug are concomitantly/simultaneously administered.
24. The method according any one of claims 17 to 23, wherein PPVO and the at least one different antiviral drug is provided in separate single unit form or as a combination products selected from the group comprising: tablets, capsules, lozenges, particularly acid-resistant capsules, drops, patches, depot administration forms, solutions, solutions for injection, solution for infusion, dilutions, creams, ointments, salves, powders, powder for reconstitution, powder for reconstitution and infusion, and/or sprays.
25. The method according any one of claims 17 to 24, wherein PPVO and/or the at least one different antiviral drug are formulated for intravenous, intramuscular, oral, parentéral, topical, intradermal, and/or subcutaneous administration.
26. The method according to any one of claims 17 to 25, wherein said individual is selected from the group of patients with acute HBV infection, chronic HBV infection, patients with détectable HBsAg, patients with détectable HBV RNA, patients with détectable HBV DNA, patients with détectable cccDNA, patients with liver inflammation, patients with liver steatosis, patients with liver fibrosis, patients with liver cirrhosis, patients with liver cancer, patients with hepatocellular carcinoma, asymptomatic or acutely or chronically infected patients, patients subjected to antiviral treatment, patients that do not respond to antiviral treatment with antiviral drugs according to any one of the preceding claims, or patients that hâve acquired résistance to at least one antiviral drug, patients that are co-infected with at least one additional pathogenic virus selected from the group comprising deltavirus, retroviridae, herpesviridae, poxviridae, parvoviridae, adenoviridae, picomaviridae, hepadnaviridae, flaviviridae, orthomyxoviridae, paramyxoviridae, papovaviridae, polyomaviridae, rhabdoviridae, coronaviridae, bunyaviridae, arenaviridae, reoviridae, and togaviridae.
27. The method according to any one of claims 17 to 26, wherein the dose of PPVO is in the range of 1 x 106 - 1 x 1010 viral particles, and/or wherein the dose of the at least one different antiviral drug is selected according to the manufacturer’s instructions.
28. The method according to any one of claims 17 to 27, wherein PPVO and the at least one different antiviral drug are administered for < 72 weeks, preferably < 60 weeks, more preferably < 48 weeks, < 36 weeks, < 24 weeks, <_12 weeks, <6 weeks, < 4 weeks, < 2 weeks, or <1 week.
29. A method for the réduction of HBV viral load in a HBV-infected patient in need thereof comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
30. A method for the réduction of HBsAg load in a HBV-infected patient in need thereof comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
31. A method for the réduction of liver damage, liver cirrhosis, and/or liver fibrosis, in a HBV-infected patient in need thereof comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
32. A method for inducing liver tissue régénération in a HBV-infected patient in need thereof comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
33. A method for reducing side-effects associated with the treatment of a HBV-infected patient, wherein said side-effects are caused by the treatment with interferons and/or nucleotide/nucleoside analogues comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims, in particular the réduction of side-effects selected from the group comprising fever, tissue inflammation, psychological disturbances, and/or hematological disturbances.
34. A method for the réduction of HBeAg load in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
35. A method for the restoration and/or réactivation of the immune response in a HBVinfected patient in need thereof comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
36. A method of reducing the amount of HBV DNA, eliminating HBV DNA and/or silencing HBV DNA, in particular cccDNA in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
37. A method of preventing the de novo formation of cccDNA in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
38. A method of inhibiting or reducing the expression of HBV proteins in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
39. A method of suppressing réplication of HBV in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
40. A method of éradication of HBV in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
41. A method of breaking immunological tolérance towards HBV infections in a HBVinfected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
42. A method of breaking tolérance towards HBsAg and/or HBeAg in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
43. A method of inducing HBsAg-specific antibodies in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
44. A method of inducing HBeAg-specific antibodies in a HBV-infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
45. A method of slowing down or inhibiting the progression of steatosis in a HBV- infected patient comprising administering an effective amount of PPVO and an effective amount of at least one different antiviral drug as defined in any of the foregoing claims.
46. A method according to any one of the preceding claims 17 to 45, wherein PPVO and the at least one different antiviral drug are administered for < 72 weeks, preferably < 60 weeks, more preferably < 48 weeks, < 24 weeks, <.12 weeks, <6 weeks, < 4 weeks, < 2 weeks, or <1 week.
47. A médicinal kit product comprising a first container comprising a pharmaceutical compositions comprising PPVO, preferably inactivated PPVO, and a second container comprising a pharmaceutical compositions comprising at least one different antiviral drug as defined in any one of the preceding claims or a pharmaceutical composition comprising PPVO, preferably inactivated PPVO, and at least one different antiviral drug as defined in any one of the preceding claims in form of a combined formulation, and optionally instructions for use, pharmaceutically acceptable media for reconstitution, syringes, and/or microneedles.
48. The médicinal kit product according to claim 47, wherein the compositions comprising PPVO, preferably inactivated PPVO, and the pharmaceutical composition comprising at least one different antiviral drug are formulated as tablets, capsules, lozenges, particularly acid-resistant capsules, drops, patches, depot administration forms, solutions, solutions for injection, solution for infusion, dilutions, creams, ointments, salves, powders, powder for reconstitution, powder for reconstitution and infusion, and/or sprays.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17189890.1 | 2017-09-07 | ||
| EP17196684.9 | 2017-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA19692A true OA19692A (en) | 2020-12-31 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018327688B2 (en) | Combination therapies of Hepatitis B Virus (HBV)-infected individuals using Parapoxvirus ovis (PPVO) and at least one further antiviral drug | |
| US20200000825A1 (en) | Methods and compositions for treating and preventing viral infections | |
| Alfaiate et al. | Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options | |
| Giersch et al. | Hepatitis B and delta virus: advances on studies about interactions between the two viruses and the infected hepatocyte | |
| US20180110796A1 (en) | Compositions and methods for the treatment of hbv infection | |
| CN109467566B (en) | Bis-diazabicyclo compounds for use in the treatment and/or prevention of diseases or disorders associated with hepatitis virus | |
| Yan et al. | CCL19 enhances CD8+ T-cell responses and accelerates HBV clearance | |
| CN108883156A (en) | Hepatitis delta viral infection is treated with interferon lambda | |
| JP2014532657A (en) | Methods and compositions for treating hepatitis C virus | |
| JPWO2018193902A1 (en) | Antiviral effect against hepatitis B virus by microRNA | |
| Zhou et al. | Different antiviral effects of IFNα and IFNβ in an HBV mouse model | |
| Bassit et al. | Moving fast toward hepatitis B virus elimination | |
| EP3395363B1 (en) | Compounds for use in treating hbv-and hcv-related conditions | |
| OA19692A (en) | Combination therapies of hepatitis B virus (HBV)-infected individuals using Parapoxvirus ovis (PPVO) and at least one further antiviral drug. | |
| Zhu et al. | Adenovirus-based gene therapy during clevudine treatment of woodchucks chronically infected with woodchuck hepatitis virus | |
| EA044847B1 (en) | COMBINED THERAPY FOR PATIENTS INFECTED WITH HEPATITIS B VIRUS USING PARAPOXVIRUS OVIS AND AN ANTIVIRAL AGENT | |
| Wen et al. | Exploiting new potential targets for anti-hepatitis B virus drugs | |
| Chen et al. | Establishment and application of hepatitis B virus persistent replication model in IFNAR−/− mouse | |
| KR20110031250A (en) | Combination therapies with l-fmau for the treatment of hepatitis b virus infection | |
| WO2022115765A1 (en) | Treatment of hepatitis e virus infection with interferon lambda | |
| Akbar et al. | Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical | |
| Zhang et al. | Miltefosine reduces coxsackievirus B3 lethality of mice with enhanced STAT3 activation | |
| JP2021134181A (en) | Anti-hepatitis B virus agent | |
| TW202345859A (en) | Methods for treating hepatitis b virus infection | |
| CN116716326A (en) | Hepatitis B mRNA, vaccine and use thereof |